Cleared Traditional

K242719 - ELEXIR 2.0 (ALLIVE3) (FDA 510(k) Clearance)

Class II Neurology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K242719 · Nu Eyne Co., Ltd. · Neurology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2024
Decision
57d
Days
Class 2
Risk

K242719 is an FDA 510(k) clearance for the ELEXIR 2.0 (ALLIVE3). Classified as Stimulator, Nerve, Electrical, Transcutaneous, For Migraine (product code PCC), Class II - Special Controls.

Submitted by Nu Eyne Co., Ltd. (Seoul, KR). The FDA issued a Cleared decision on November 6, 2024 after a review of 57 days - a notably fast clearance cycle.

This device falls under the Neurology FDA review panel, regulated under 21 CFR 882.5891 - the FDA neurology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Nu Eyne Co., Ltd. devices

Submission Details

510(k) Number K242719 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 10, 2024
Decision Date November 06, 2024
Days to Decision 57 days
Submission Type Traditional
Review Panel Neurology (NE)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
91d faster than avg
Panel avg: 148d · This submission: 57d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 882.5891
Definition Used To Apply An Electrical Current To A Patient's Cranium Through Electrodes Placed On The Skin.
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Neurology devices follow this clearance model.

Regulatory Peers - PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine

All 17
Devices cleared under the same product code (PCC) and FDA review panel - the closest regulatory comparables to K242719.
Enso for Migraine
K254216 · Hinge Health, Inc. · Apr 2026
CEFALY Connected - OTC, CEFALY Connected - Rx
K234029 · Cefaly Technology · Jul 2024
DOOPANG
K232749 · Ybrain, Inc. · Jun 2024
Milieve (YPS-301BD)
K233751 · Soterix Medical, Inc. · Jun 2024
TENS device-HeadaTerm 2 (Model: YF-HT2)
K230782 · Wat Medical Technology, Inc. · Feb 2024
Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx, Cefaly Dual Connected - OTC, Cefaly Dual Connected - Rx
K212071 · Cefaly Technology · Dec 2022